Behavioral pediatrics : mental health and management / Donald E. Greydanus.

Format:

Book

Author/Creator:

Greydanus, Donald E., author.

Series:

Pediatrics, Child and Adolescent Health

Language:

English

Subjects (All):

Child psychiatry.

Child psychiatry--Research.

Physical Description:

1 online resource (352 pages)

Edition:

1st ed.

Place of Publication:

New York, NY : Nova Science Publishers, Inc., [2022]

Summary:

Pediatricians can provide a wide variety of care to children and adolescents with complex disorders, depending on their training as well as interests, but they need to work closely with professionals in psychiatry and psychology when dealing with complex issues in mental health disorders. Behavioral health screening is therefore an important task of pediatricians and behavioral pediatricians as they evaluate their pediatric patients. Section one looks at what is called special issues in mental health that include suicide/self-harm in pediatrics, childhood-onset schizophrenia, child abuse/maltreatment, mental health issues of chronic disorders (i.e., diseases of the cardiovascular system, the kidneys and the liver), and behavioral/emotional effects of COVID-19 on children/adolescents. Section two covers various aspects of substance use disorders (SUD) that include SUD neurobiology, substance use/abuse in adolescents, an overview on cannabis, psychosocial treatments of SUDs, pharmacologic management of SUDs, and pharmacology of tobacco abuse. Section three provides a critical look at mental health management that includes psychotherapeutic interventions (i.e., children, adolescents and families), behavioral/cognitive behavioral therapies and principles of psychopharmacologic management in pediatric persons.

Contents:

Intro

Dedication for this 5th Edition

Contents

Forewords

First edition

Second edition

Third edition

Fourth edition

Current fifth edition

References

Preface

Section one: Special issues (editor: Donald E. Greydanus)

Chapter 1

Suicide and self-harm in children and adolescents

Abstract

Introduction

Epidemiology

Global suicide rates

Suicide in young children

Risk factors

Previous suicide attempts or self-harm behaviors

Gender

Sexual orientation

Familial factors

Stressors

Access to lethal means

Media and screen time

Protective factors

Parental supervision

Social support

Religion

Prevention

Lethal means restriction

School-based programs

School personnel training (gatekeeper training)

Student education and skills training

Suicide risk screening

Community-based programs

Healthcare-based programs

Media related prevention strategies

Assessment

Treatment

Psychotherapy

Pharmacological treatments

Conclusion

Chapter 2

Psychotic disorders in children and adolescents

Prodromal phase/Clinical high-risk phase

Delusions

Hallucinations

Disorganized speech

Disorganized behavior

Negative symptoms

Etiology

Childhood adversity

Genetic vulnerability

Pathogenesis

Differential diagnosis

Substance use disorders (SUD) and drug intoxications

Post-traumatic stress disorder (PTSD)

Autism spectrum disorders

Schizoaffective disorders

Mood disorders

Medical diseases

Nonpsychotic Children

Evaluation

Approach considerations

Consultations

Pharmacotherapy

Prodromal stage

Medications for Prodromal stage

Antipsychotics

Evidence

Omega-3 fatty acids

Antidepressants

Summary.

First episode psychosis

Positive symptoms

Choosing the initial antipsychotic

Long-acting injectable (LAI) formulations

Treatment resistant schizophrenia

Side effects

Second-generation antipsychotics

First-generation antipsychotics

Side effect differences when compared to adults

Treatment of side effects

Electroconvulsive Therapy (ECT)

Psychosocial interventions

Chapter 3

Recognizing and treating the emotional and behavioral effects of child maltreatment

Abbreviations

Extent of the problem

Behavioral issues for young children

Behavioral issues for adolescents

Issues related to the COVID-19 pandemic

Medical evaluation (Medical history, examination and diagnosis)

Skin lesions in physical abuse

Sexual abuse

Psychological maltreatment

Physical and medical care neglect

Mental health screening and evaluation

PTSD assessment measures for pre-school aged children

PTSD assessment measures for school-aged children

General assessment measures for youth

Mental health screening and PTSD evaluation for adolescents

Reporting

Shared treatment components

Pharmacologic treatment

Empirically supported non-pharmacologic treatment

Chapter 4

Mental health and chronic disease: Issues in cardiovascular disease

Quality of Life

Emotional and behavioral difficulties

Cognitive and academic impact

Quality of life in pediatric heart transplant patients

Parental mental health

Psychopharmacological considerations in children with CHD/CVD

Hypotension, syncope, and rhythm disturbances

QTc prolongation and cardiac conduction delays

Stimulants and sudden cardiac death

Conclusion.

References

Chapter 5

Mental health considerations in renal disease

Impact on quality of life for the adolescents and families

The quality of life experience of the caregiver

Common psychiatric disorders in adolescents with renal disease

Depression and other mood symptoms

Anxiety disorders

Cognitive and learning difficulties

Psychopharmacology considerations

Pharmacodynamics and pharmacokinetics

Renal considerations for psychotropic agents

Special considerations: Dialysis patients

Chapter 6

The pediatric liver: Mental health considerations

Mental health issues in liver transplantation

Medical Adherence in Pediatric Liver Transplant Recipients

Psychological factors influencing adherence

Identifying barriers to adherence

Interventions for improving adherence

The transition of care and medical adherence

Measuring medication adherence

The importance of pre-operative psychological screening

Post-operative neuropsychological outcomes and hepatic encephalopathy

The emotional well-being of the pediatric transplant patient: Trauma, family stress, health-related quality of life, and the importance of psychological support

Multidisciplinary team

Health-related quality of life (HRQoL)

Wilson's disease

Hepatitis C

Metabolic side-effects of psychotropic medications

Chapter 7

Behavioral/emotional effects of COVID-19 on children and teens

COVID-19 in children

Changes for families

Mental health-general population

Disproportionately negative impact

Disruption of critical mental health services

Pediatrics in pandemia

Psychological screening and referral

Management of chronic conditions.

Guidance specific to mental health + general COVID

General guidance during a pandemic

Specific guidance for mental and behavioral wellness

Identifying parental anxiety

Disclaimer

Additional resources:

No-cost materials for families and children

Section two: Perspectives of substance use disorders

Chapter 8

Neurobiology of substance use disorders

General concepts

Dopamine

D1, D5 receptors

D2 and D3 receptors

Serotonin and norepinephrine

Cannabinoid (CB1) receptors

γ-Aminobutyric acid (GABA)

Glutamate receptors

Magnetic resonance imaging (MRI)

Neuropharmacology of specific drugs

Stimulants

Alcohol

Opioids

Nicotine/tobacco

Cannabinoids

Chapter 9

Substance use and abuse in adolescents: An overview

DSM-5

YRBS 2019

Energy drinks

Designer drugs

Tobacco

2019 YRBS

General issues

Pharmacologic management

Non-nicotine therapy

Marijuana (Cannabis)

Alcohol effects

Management of alcohol abuse

Amphetamines

Methamphetamine

Cocaine

Management of cocaine addiction

Heroin

Management of opioid addiction

Hallucinogenic drugs

Phencyclidine (PCP)

Lysergic acid diethylamine (LSD)

Tryptamines

MDMA (Ecstasy)

"Date rape" drugs

Flunitrazepam (Rohypnol)

Gamma-hydroxybutyrate (GHB)

Gamma-butyro-lactone (GBL)

Ketamine

Inhalants

Barbiturates

Acknowledgment

Chapter 10

Cannabis: Current concepts and conundrums

Cannabis sativa plant

Prevalence

Consumption of cannabis (marijuana)

Cannabis and other drug use

Endocannabinoid system

Medicinal cannabis.

Synthetic cannabinoids (cannabinoid designer drugs

cannabimimetics)

Cannabis lab testing

Medical adverse effects

Cannabis hyperemesis syndrome

Dental effects of cannabis

Pulmonary effects

Cannabis and cancer

Cardiovascular effects

Motor vehicle accidents

Sports doping

Adverse effects: Psychiatric

Cannabis and ADHD

Cannabis-related psychiatric disorders

Cannabis withdrawal syndrome

Addiction

Cannabis and psychosis

Management

Pharmacologic therapies

Cannabis intoxication

Cannabis withdrawal

Cannabis-associated psychosis

Cannabis use disorder

Oxytocin

NAC

Others

Chapter 11

Psychosocial treatments for substance use disorders

Primary prevention programs

Assessment as an intervention

Motivational treatments

Motivational interviewing

Pre-contemplation stage

Contemplation stage

Preparation stage

Action stage

Maintenance stage

Contingency management and community reinforcement approaches

Community reinforcement approach (CRA)

Cognitive-behavioral approaches

Functional analysis

Drug refusal skills (DRS)

Relapse prevention (RP)

Family interventions

Multidimensional family therapy (MDFT)

Chapter 12

Substance use disorders in adolescents: Pharmacologic management

Drug interactions

Heroin dependence management

Acknowledgments

Chapter 13

Use of pharmacologic agents for smoking cessation

Chemistry and pharmacology

Effects on health

Behavioral approaches to smoking cessation

Pharmacological agents

Varenicline

Bupropion sustained release (SR).

Nicotine replacement therapies.

Notes:

Description based on print version record.

Other Format:

Print version: Greydanus, Donald E. Behavioral Pediatrics: Mental Health and Management. Fifth Edition

ISBN:

9798886971064